DOP2018000127A - Derivados novedosos de diamino piridina - Google Patents

Derivados novedosos de diamino piridina

Info

Publication number
DOP2018000127A
DOP2018000127A DO2018000127A DO2018000127A DOP2018000127A DO P2018000127 A DOP2018000127 A DO P2018000127A DO 2018000127 A DO2018000127 A DO 2018000127A DO 2018000127 A DO2018000127 A DO 2018000127A DO P2018000127 A DOP2018000127 A DO P2018000127A
Authority
DO
Dominican Republic
Prior art keywords
novel derivatives
compounds
methods
present
jak
Prior art date
Application number
DO2018000127A
Other languages
English (en)
Inventor
Thoma Gebhard
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of DOP2018000127A publication Critical patent/DOP2018000127A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe derivados novedosos de diamino piridina que uestran propiedades de modulación de JAK. La presente invención también se refiere a composiciones farmacéuticas que comprenden estos nuevos compuestos, métodos de uso de dichos compuestos en el tratamiento de diversas enfermedades y trastornos que son susceptibles a la modulación de JAK, y procedimientos para preparar los compuestos descritos más adelante.
DO2018000127A 2015-11-26 2018-05-21 Derivados novedosos de diamino piridina DOP2018000127A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15196542 2015-11-26

Publications (1)

Publication Number Publication Date
DOP2018000127A true DOP2018000127A (es) 2018-10-31

Family

ID=54705130

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000127A DOP2018000127A (es) 2015-11-26 2018-05-21 Derivados novedosos de diamino piridina

Country Status (35)

Country Link
US (3) US10570096B2 (es)
EP (2) EP3757097B1 (es)
JP (1) JP6634157B2 (es)
KR (1) KR102097878B1 (es)
CN (2) CN112851578A (es)
AU (1) AU2016359438B2 (es)
BR (1) BR112018009540A2 (es)
CA (1) CA3005159A1 (es)
CL (1) CL2018001370A1 (es)
CO (1) CO2018005354A2 (es)
CR (1) CR20180285A (es)
CU (1) CU24506B1 (es)
CY (1) CY1123543T1 (es)
DK (1) DK3380465T3 (es)
DO (1) DOP2018000127A (es)
EA (1) EA035899B1 (es)
EC (1) ECSP18041731A (es)
ES (2) ES2916582T3 (es)
HK (1) HK1253530A1 (es)
HR (1) HRP20201662T1 (es)
HU (1) HUE052345T2 (es)
IL (1) IL259360B (es)
LT (1) LT3380465T (es)
MX (1) MX2018006495A (es)
MY (1) MY195905A (es)
PE (1) PE20181071A1 (es)
PH (1) PH12018501019A1 (es)
PL (2) PL3757097T3 (es)
PT (2) PT3380465T (es)
RS (1) RS60946B1 (es)
RU (2) RU2020124922A (es)
SA (1) SA518391657B1 (es)
SG (1) SG11201803760VA (es)
SI (1) SI3380465T1 (es)
WO (1) WO2017089985A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3380465T (pt) * 2015-11-26 2020-10-23 Novartis Ag Derivados de diamino piridina
BR112021013377A2 (pt) 2019-01-11 2021-09-14 Novartis Ag Inibidores de lta4h para o tratamento de hidradenite supurativa
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
KR101149295B1 (ko) * 2006-12-08 2012-07-05 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
DK2134689T3 (da) * 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
EP2361902A4 (en) 2008-11-21 2012-04-25 Astellas Pharma Inc 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
CA2745004C (en) 2008-11-28 2014-07-15 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
ES2473584T3 (es) 2009-01-23 2014-07-07 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
US9102625B2 (en) 2010-11-01 2015-08-11 Portola Pharmaceuticals, Inc. Nicotinamides as JAK kinase modulators
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
EP2909174A1 (en) 2012-10-19 2015-08-26 F. Hoffmann-La Roche AG Inhibitors of syk
ES2914793T3 (es) * 2012-11-08 2022-06-16 Bristol Myers Squibb Co Compuestos heterocíclicos sustituidos con amida, útiles como moduladores de la respuesta de IL-12, IL-23 y/o IFN-alfa
WO2014074675A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
MX2015005272A (es) * 2012-11-08 2015-07-14 Squibb Bristol Myers Co Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de las respuestas de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifnalfa).
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
JP2015014960A (ja) 2013-07-05 2015-01-22 ソニー株式会社 情報処理装置、および記憶媒体
AU2014339897A1 (en) 2013-10-24 2016-04-21 Abbvie Inc. JAK1 selective inhibitor and uses thereof
JP2018502837A (ja) 2014-12-03 2018-02-01 アールエックスアイ ファーマシューティカルズ コーポレーション 遺伝子調節アプローチを用いた円形脱毛症の処置方法
PT3380465T (pt) * 2015-11-26 2020-10-23 Novartis Ag Derivados de diamino piridina

Also Published As

Publication number Publication date
HK1253530A1 (zh) 2019-06-21
SI3380465T1 (sl) 2020-11-30
PL3380465T3 (pl) 2021-01-25
US10570096B2 (en) 2020-02-25
CU24506B1 (es) 2021-04-07
AU2016359438B2 (en) 2019-05-02
EP3757097B1 (en) 2022-03-30
HRP20201662T1 (hr) 2020-12-25
RU2018122953A3 (es) 2020-01-29
EA201891258A1 (ru) 2018-10-31
CR20180285A (es) 2018-07-16
LT3380465T (lt) 2020-11-10
PT3757097T (pt) 2022-06-20
RU2020124922A (ru) 2020-08-10
PH12018501019A1 (en) 2018-12-17
PL3757097T3 (pl) 2022-07-25
MX2018006495A (es) 2018-08-15
IL259360A (en) 2018-07-31
US20200140386A1 (en) 2020-05-07
CY1123543T1 (el) 2022-03-24
BR112018009540A2 (pt) 2018-11-06
ECSP18041731A (es) 2018-06-30
KR102097878B1 (ko) 2020-04-06
CA3005159A1 (en) 2017-06-01
PE20181071A1 (es) 2018-07-04
RS60946B1 (sr) 2020-11-30
IL259360B (en) 2021-05-31
SA518391657B1 (ar) 2021-02-22
SG11201803760VA (en) 2018-06-28
US20220177432A1 (en) 2022-06-09
RU2730007C2 (ru) 2020-08-14
KR20180067681A (ko) 2018-06-20
EA035899B1 (ru) 2020-08-28
HUE052345T2 (hu) 2021-04-28
EP3757097A1 (en) 2020-12-30
MY195905A (en) 2023-02-27
WO2017089985A1 (en) 2017-06-01
CN108349937B (zh) 2021-02-09
AU2016359438A1 (en) 2018-05-31
US11274080B2 (en) 2022-03-15
ES2916582T3 (es) 2022-07-01
JP2019503343A (ja) 2019-02-07
CO2018005354A2 (es) 2018-05-31
DK3380465T3 (da) 2020-10-26
CN108349937A (zh) 2018-07-31
ES2829052T3 (es) 2021-05-28
CN112851578A (zh) 2021-05-28
EP3380465A1 (en) 2018-10-03
JP6634157B2 (ja) 2020-01-22
PT3380465T (pt) 2020-10-23
US20180354904A1 (en) 2018-12-13
RU2018122953A (ru) 2019-12-26
CL2018001370A1 (es) 2018-07-27
CU20180044A7 (es) 2018-10-04
EP3380465B1 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CY1123853T1 (el) Ρυθμιστες nrf2
BR112018073384A2 (pt) polinucleotídeos moduladores
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2019000115A1 (es) Compuestos y métodos para la modulación de smn2.
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
ECSP16074478A (es) Compuestos novedosos
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
EP4219507A3 (en) Thienopyrimidinone nmda receptor modulators and uses thereof
CY1123543T1 (el) Παραγωγα διαμινοπυριδινης
ECSP16074207A (es) Pirazinas moduladoras de gpr6
TW201713686A (en) Methods for preparing modified von Willebrand factor
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
UY37255A (es) Derivados novedosos de diamino piridina
UY35443A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina